We are developing ferroptosis inhibitors to prevent delayed graft function (DGF) in kidney transplantation, a condition affecting up to 50% of deceased donor transplants. DGF leads to poor outcomes, including increased rejection, return to dialysis, and reduced survival rates. Our lead compounds, formulated for both oral and IV use, have shown >50% reduction in DGF biomarkers in preclinical models. 

We are seeking funding to test the IV formulation in additional in vivo models, fully characterize pharmacokinetics and toxicology, and evaluate efficacy in a human kidney perfusion model. This approach aims to enhance transplant success and patient quality of life.